Korean J Ophthalmol.  2013 Aug;27(4):268-275. 10.3341/kjo.2013.27.4.268.

Foveal Thickness between Stratus and Spectralis Optical Coherence Tomography in Retinal Diseases

• Roh YR
• Park KH
• Woo SJ

• KMID: 1705423
• DOI: http://doi.org/10.3341/kjo.2013.27.4.268

Abstract

PURPOSE
To compare the foveal thickness (FT) parameters measured by Stratus optical coherence tomography (OCT) and Spectralis OCT in various retinal diseases and to construct conversion formulas between the two types of OCT devices.
METHODS
We examined 366 consecutive patients (475 eyes) with retinal diseases and 13 normal controls (13 eyes). The patients were categorized into eight retinal disease groups. The mean amount and distribution of foveal thickness differences (FTD) measured by Stratus and Spectralis OCT were determined, and conversion formulas were constructed for Stratus OCT FT from Spectralis OCT FT for each retinal disease group.
RESULTS
Among retinal diseases, the mean FTD was significantly larger in exudative age-related macular degeneration (AMD) patients (mean +/- SD, 94.0 +/- 55.0 microm) compared to normal subjects (66.2 +/- 11.7 microm; p < 0.0001). The proportion of eyes with a mean FTD outside 1.96 standard deviations of normal subject FTD was greatest in the exudative AMD (50.0%) group and smallest in the macular hole (18.2%) group. The predicted FTs obtained through the conversion formulas showed lower variance than the actual FTD values, especially in the exudative AMD group. The prediction line for exudative AMD deviated most from that of normal subjects.
CONCLUSIONS
FTD shows diverse values and variances among various retinal diseases, especially in exudative AMD, which indicates that Stratus OCT FT cannot be predicted from Spectralis OCT FT by FTD value alone. We constructed statistically significant conversion formulas, which provided more reliable methods to predict Stratus OCT-measured FT from Spectralis OCT measurements for different retinal disease groups.

Keyword

Foveal thickness; Optical coherence tomography; Prediction; Spectral-domain; Time-domain

MeSH Terms

Adolescent
Adult
Aged
Aged, 80 and over
Cross-Sectional Studies
Female
Fovea Centralis/*pathology
Humans
Male
Middle Aged
Predictive Value of Tests
Retinal Diseases/*pathology
Retrospective Studies
*Tomography, Optical Coherence
Young Adult

Figure

• 

  Fig. 1 Representative cross-sections taken by Stratus (A) and Spectralis (B) optical coherence tomography (OCT) in normal controls, and the measurement of foveal thickness (FT) by Stratus OCT (C) and Spectralis OCT (D) in exudative age-related macular degeneration (AMD). The borders of retinas in normal controls measured by Stratus OCT are outlined as white lines, (A) and those measured by Spectralis OCT are outlined as red lines (B). Meanwhile, the FT of Stratus OCT in exudative AMD, which did not include choroidal neovascularization (CNV) thickness (white lines), is indicated by 'a' (C). However, the FT of Spectralis OCT in exudative AMD included CNV thickness (red lines), and the FT measured by Spectralis OCT before and after considering CNV thickness is indicated by 'b' and 'c', respectively (D).

• 

  Fig. 2 (A) The mean foveal thickness difference (FTD) of normal subjects and subjects with retinal diseases. The mean FTD was greatest in the exudative age-related macular degeneration (AMD) group, and it was greater than that of normal controls (p < 0.0001, generalized estimating equations [GEE]). (B) The means and standard deviations (SD) of the differences between the virtual foveal thickness (FT) of Stratus optical coherence tomography (OCT) calculated by the conversion formulas and the actual FT measured by Stratus OCT in each group. The SD was decreased by applying conversion formulas, especially in the exudative AMD group. The horizontal lines within the white boxes indicate medians, the upper and lower limits of the white boxes indicate 75th and 25th percentiles, respectively, the upper and lower limits of the whiskers indicate 90th and 10th percentiles, and the dots over and under the whiskers indicate the values outside the 90th and 10th percentiles. ERM = epiretinal membrane; MH = macular hole; DR = diabetic retinopathy; RVO = retinal vein occlusion; CSC = central serous chorioretinopathy; CNV = choroidal neovascularization.

• 

  Fig. 3 The proportions of eyes with different retinal disorders with a mean foveal thickness difference (FTD) that was 1.96 standard deviations (SDs) outside the mean FTD of normal subjects. The proportion was greatest in the exudative age-related macular degeneration (AMD) group. The numbers in parentheses indicate the number of patients in each group. ERM = epiretinal membrane; MH = macular hole; DR = diabetic retinopathy; RVO = retinal vein occlusion; CSC = central serous chorioretinopathy.

• 

  Fig. 4 The graphs of the conversion formulas between the foveal thickness (FT) measured by Stratus optical coherence tomography (OCT) and Spectralis OCT in normal subjects and subjects with various retinal diseases. ERM = epiretinal membrane; MH = macular hole; DR = diabetic retinopathy; RVO = retinal vein occlusion; AMD = age-related macular degeneration; CSC = central serous chorioretinopathy.

Reference

1. Leung CK, Cheung CY, Weinreb RN, et al. Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2008; 49:4893–4897.

2. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991; 254:1178–1181.

3. Hee MR, Izatt JA, Swanson EA, et al. Optical coherence tomography of the human retina. Arch Ophthalmol. 1995; 113:325–332.

4. Puliafito CA, Hee MR, Lin CP, et al. Imaging of macular diseases with optical coherence tomography. Ophthalmology. 1995; 102:217–229.

5. Thomas D, Duguid G. Optical coherence tomography: a review of the principles and contemporary uses in retinal investigation. Eye (Lond). 2004; 18:561–570.

6. Forte R, Cennamo GL, Finelli ML, de Crecchio G. Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye (Lond). 2009; 23:2071–2078.

7. Paunescu LA, Schuman JS, Price LL, et al. Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using Stratus OCT. Invest Ophthalmol Vis Sci. 2004; 45:1716–1724.

8. Gurses-Ozden R, Teng C, Vessani R, et al. Macular and retinal nerve fiber layer thickness measurement reproducibility using optical coherence tomography (OCT-3). J Glaucoma. 2004; 13:238–244.

9. Kakinoki M, Sawada O, Sawada T, et al. Comparison of macular thickness between Cirrus HD-OCT and Stratus OCT. Ophthalmic Surg Lasers Imaging. 2009; 40:135–140.

10. Joeres S, Tsong JW, Updike PG, et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007; 48:4300–4307.

11. Drexler W, Sattmann H, Hermann B, et al. Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch Ophthalmol. 2003; 121:695–706.

12. Sayanagi K, Sharma S, Kaiser PK. Comparison of retinal thickness measurements between three-dimensional and radial scans on spectral-domain optical coherence tomography. Am J Ophthalmol. 2009; 148:431–438.

13. Wojtkowski M, Bajraszewski T, Targowski P, Kowalczyk A. Real-time in vivo imaging by high-speed spectral optical coherence tomography. Opt Lett. 2003; 28:1745–1747.

14. Alam S, Zawadzki RJ, Choi S, et al. Clinical application of rapid serial fourier-domain optical coherence tomography for macular imaging. Ophthalmology. 2006; 113:1425–1431.

15. Srinivasan VJ, Wojtkowski M, Witkin AJ, et al. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2006; 113:2054.e1–2054.e14.

16. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148:43–58.e1.

17. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008; 145:854–861.

18. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009; 116:1142–1150.

19. Grover S, Murthy RK, Brar VS, Chalam KV. Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci. 2010; 51:2644–2647.

20. Han IC, Jaffe GJ. Comparison of spectral- and time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. Am J Ophthalmol. 2009; 147:847–858. 858.e1

21. Lammer J, Scholda C, Prunte C, et al. Retinal thickness and volume measurements in diabetic macular edema: a comparison of four optical coherence tomography systems. Retina. 2011; 31:48–55.

22. Ibrahim MA, Sepah YJ, Symons RC, et al. Spectral- and time-domain optical coherence tomography measurements of macular thickness in normal eyes and in eyes with diabetic macular edema. Eye (Lond). 2012; 26:454–462.

23. Krebs I, Hagen S, Smretschnig E, et al. Conversion of Stratus optical coherence tomography (OCT) retinal thickness to Cirrus OCT values in age-related macular degeneration. Br J Ophthalmol. 2011; 95:1552–1554.

24. Sayanagi K, Sharma S, Yamamoto T, Kaiser PK. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology. 2009; 116:947–955.

25. Cukras C, Wang YD, Meyerle CB, et al. Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices. Eye (Lond). 2010; 24:775–783.

26. Menke MN, Dabov S, Knecht P, Sturm V. Reproducibility of retinal thickness measurements in patients with age-related macular degeneration using 3D Fourier-domain optical coherence tomography (OCT) (Topcon 3D-OCT 1000). Acta Ophthalmol. 2011; 89:346–351.

27. Ray R, Stinnett SS, Jaffe GJ. Evaluation of image artifact produced by optical coherence tomography of retinal pathology. Am J Ophthalmol. 2005; 139:18–29.

28. Leung CK, Chan WM, Chong KK, et al. Alignment artifacts in optical coherence tomography analyzed images. Ophthalmology. 2007; 114:263–270.